Zynerba Pharmaceuticals (ZYNE)

[lumpy9200]

Disappointing results and I understand why the stock is taking a hit. With that said, Zygel DID reach stat sig with patients showing "full methylation". That was 80% of the trial participants, and 60% of all Fragile X cases in the world (estimate, according to ZYNE management).

Bottom line (for me)....if Zygel works for 60% of the Fragile X population, the drug WILL get approved and WILL bring in significant money to Zynerba. Obviously not as good as helping everyone with FX, but 60% is a big number. And with no serious adverse side effects, it's a no-brainer for doctors to prescribe to patients. Maybe I'm just looking through rose colored glasses here, but I think sales to potential 60% of the group is good enough to warrant the stock going UP today, not down. Time will tell where this heads....